Commentary Open Access
Volume 3 | Issue 2 | DOI: https://doi.org/10.33696/cancerimmunol.3.044
Exosomes, PD-L1 and aGvHD: Perspectives for WJMSCmediated Therapy
Meizhang Li1, Haitham Abdelhakim2, Mitchell W. Braun1, Andrew K. Godwin1,3,4,*
- 1Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA
- 2Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160,USA
- 3Department of Microbiology, Molecular Genetics and Immunology, Kansas City, KS 66160, USA
- 4The University of Kansas Cancer Center, Kansas City, KS 66160, USA
Corresponding Author
Andrew K. Godwin, agodwin@kumc.edu
Received Date: March 08, 2021
Accepted Date: March 29, 2021
Li M, Abdelhakim H, Braun MW, Godwin AK. Exosomes, PD-L1 and aGvHD: Perspectives for WJMSC-mediated Therapy. J Cancer Immunol. 2021; 3(1): 98-103.
Copyright: © 2021 Li M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Exosomes, PD-L1 and aGvHD: Perspectives for WJMSCmediated Therapy
Tumor-derived small extracellular vesicles or exosomes which carry the checkpoint PD-L1 are directly involved in immune evasion and uncontrolled tumor growth. We have recently reported that PD-L1 is also enriched on Wharton’s Jelly Mesenchymal Stromal Cell (WJMSC)-associated exosomes.
Biomarkers of Pembrolizumab Efficacy in First-Line Advanced PD-L1 ≥ 50% Non-Small Cell Lung Cancer Treatment
Lung cancer is the leading cause of cancer death worldwide. In 2020, a total of 19 million cancer patients were diagnosed, of which 11.4% were lung cancer, causing 18% of all cancer deaths. In 2020 in Spain, 29,638 cases were estimated.
PD-L1 as a Novel Mediator of Lung Fibroblast to Myofibroblast Transition
Idiopathic pulmonary fibrosis (IPF) is an incurable disease that affects approximately 3 million people worldwide. Although two drugs (nintedanib and pirfenidone) have been approved for treatment of IPF, currently there is a lack of effective pharmacotherapy that could stop the progression or offer a cure for this devasting disease.
Role of PD-L1 SP263 Assay in Cancer Immunotherapy: A Comprehensive Review
Over the past decade, immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for many types of cancers, leading to significant improvements in patient survival. Treatments like nivolumab, pembrolizumab, durvalumab, and atezolizumab have shown remarkable efficacy. Among the various biomarkers used to guide ICI therapy, PD-L1 is one of the most extensively studied. The PD-L1 SP263 assay is one of the most commonly used assays for identifying PD-L1 status.